Biogen Inc. (0R1B)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 250.63 |
|---|---|
| 52-week range | 138.07 – 252.35 |
| Return, 1 month / 3 months | +11.2% / +25.1% |
| Return, 1 year / 3 years | +69.5% / −3.4% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 31.4% |
| Worst drawdown (1 year) | -13.8% |
| Average daily value traded | 0.14M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Biogen Inc. is a biotechnology company based in Cambridge, Massachusetts, that discovers, develops and markets medicines for serious neurological and neurodegenerative diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy and Alzheimer's disease, along with biosimilar medicines. The company serves patients and physicians through hospitals, clinics and specialty pharmacies, and it also works with partners on research and development programmes in neuroscience.
On this site Biogen Inc. appears as a stock on the London Exchange (UK), code 0R1B, with prices in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biogen Inc. (0R1B) trades on the London Exchange in UK. It last closed at USD 250.63 on 22 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 180 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 69.5% and over the last three months it rose 25.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 25.8% | ||
| From 52-week high | 0.0% | ||
| Momentum | 90 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 25.1% | ||
| 6-month return | 32.0% | ||
| 12-month return, skipping the last month | 52.5% | ||
| Stability (higher is calmer) | 74 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 31.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -13.8% | ||
| Liquidity | 33 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.14M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.3% |
|---|---|
| 1 month | +11.2% |
| 3 months | +25.1% |
| 6 months | +32.0% |
| 1 year | +69.5% |
| 3 years | −3.4% |
| 5 years | −5.6% |
Signals
| 50-day / 200-day average | 222.82 / 199.20 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.27 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.